We're making updates and relaunching soon. Get notified

Straight answers about GLP-1 medications

Plain-language guides on dosing, side effects, costs, and what to look for in a provider.

Relaunching Soon

  • Relaunching as an independent GLP-1 guide
  • Get notified when we relaunch
  • We only ask for your email
Get Started

One email to confirm. Unsubscribe anytime.

GLP-1 Muscle Loss: Semaglutide vs Tirzepatide on Lean Mass

You’ve heard that GLP-1 medications help with weight loss. What you may not have heard is what happens to your muscle mass during that loss. And you’ve likely heard competing claims about semaglutide versus tirzepatide: which one preserves muscle better, whether tirzepatide is “safer” because of its dual mechanism, or whether one is simply superior to the other.

The evidence is more specific than the claims. Both medications produce lean mass loss as part of overall weight loss, and that loss is similar to what happens with other approaches that produce large weight reductions. There are also well-supported ways to limit it. Here’s what the clinical data actually shows about semaglutide, tirzepatide, and muscle during weight loss.

The Fundamental Truth About Weight Loss and Lean Mass

This is important to understand first: significant weight loss generally includes some lean mass loss, not just with GLP-1 medications. A 2025 joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society notes that the fat, lean, and muscle losses seen with GLP-1 medications track with the amount of weight lost and are similar to those seen with bariatric surgery and very low-calorie diets[4].

“Lean mass” is not the same as muscle. It includes muscle, but also organs, bone, fluids, and the water inside fat tissue[6]. The joint advisory estimates that muscle makes up about half of lean body mass[4].

The FDA labels for both medications describe the overall pattern: the Wegovy label says semaglutide “lowers body weight with greater fat mass loss than lean mass loss,” and the Zepbound label says the same of tirzepatide[8][9].

The question is not “will I lose muscle?” The question is “how much muscle will I lose relative to fat, and what can I do about it?”

The Clinical Data: What STEP 1 and SURMOUNT-1 Show

Two large trials, each with a body-composition analysis, give the clearest picture so far. Both studied the FDA-approved products (semaglutide 2.4 mg, now sold as Wegovy, and tirzepatide, now sold as Zepbound), not compounded versions.

STEP 1 (semaglutide 2.4 mg weekly, published 2021)[1] enrolled 1,961 adults without diabetes for 68 weeks. Average weight change was -14.9% with semaglutide and -2.4% with placebo. According to the joint advisory’s summary of the trial’s body-composition data, of an average 13.6 kg weight reduction, 8.3 kg (62%) was fat mass and 5.3 kg (38%) was lean body mass[4]. Because muscle is about half of lean mass, the advisory estimates that roughly 20% of the weight lost was muscle[4].

SURMOUNT-1 (tirzepatide 5, 10, or 15 mg weekly, published 2022)[2] enrolled 2,539 adults without diabetes for 72 weeks. Average weight change was -15.0%, -19.5%, and -20.9% on the 5, 10, and 15 mg doses, compared with -3.1% on placebo. In a substudy of 160 participants who had DXA body-composition scans, body weight fell 21.3%, fat mass 33.9%, and lean mass 10.9% with tirzepatide (doses pooled), compared with 5.3%, 8.2%, and 2.6% with placebo. About 75% of the weight lost was fat and about 25% was lean mass, in both the tirzepatide and placebo groups, and those proportions held fairly steady across subgroups by sex, age, and amount of weight lost[5].

Notice what these numbers can and cannot tell you. They come from two different trials with different participants, methods, and reporting, so a lean mass share of about 38% in one and about 25% in the other is not evidence that either drug preserves muscle better. A 2024 review found that lean mass loss across GLP-1 trials has ranged from about 15% or less to 40% to 60% of total weight lost, and listed differences in study populations, the specific drug, and other health conditions as possible reasons[6].

Results vary. Trial results describe study participants and are not a prediction for any individual.

Semaglutide vs Tirzepatide on Muscle Loss: What the Evidence Actually Shows

The SURMOUNT-5 trial, published in 2025, compared the two medications head to head in 751 adults with obesity but without type 2 diabetes[3]. Its primary and key secondary end points were weight and waist circumference; the published results do not include a body-composition comparison.

What we know from SURMOUNT-5:

  • At 72 weeks, average weight change was -20.2% on tirzepatide (10 or 15 mg) and -13.7% on semaglutide (1.7 or 2.4 mg)[3]
  • The medications differ in mechanism (tirzepatide acts on GLP-1 and GIP receptors; semaglutide acts on GLP-1 receptors only)
  • The most common adverse events in both groups were gastrointestinal, mostly mild to moderate, and occurred mainly during dose escalation[3]

What we don’t know yet:

  • Whether either medication preserves lean mass better than the other. No head-to-head body-composition trial has been published; we did not find one in a PubMed search on October 16, 2026.

This absence of data is important. You may see claims that tirzepatide’s GIP activity protects muscle. That idea has not been tested in a head-to-head body-composition trial, so treat it as unproven.

Until that evidence exists, the fair summary is that both medications reduce lean mass along with fat, and the two cannot be ranked on muscle preservation. Because tirzepatide produced more total weight loss in SURMOUNT-5, the absolute amount of lean mass lost could be larger, but that has not been measured directly.

Why Lean Mass Loss Matters, and Why It’s Not Catastrophic

Muscle supports strength, mobility, and daily function, and it is metabolically active tissue. Losing a large amount of it can matter:

  • Loss of muscle strength and functional capacity, which matters most for older adults, who are already losing muscle with age
  • Reduced physical performance and ability to engage in activities you enjoy
  • A possible drop in the calories you burn at rest

There is also reassuring evidence. The 2024 review cited above concluded, based on MRI studies, that muscle changes with GLP-1 treatment appear to be largely adaptive: reductions in muscle volume seem in line with what would be expected for age, health status, and the amount of weight lost, and muscle quality (less fat inside the muscle) may improve[6]. The same review notes that older age and more severe illness can raise the risk of sarcopenia (age-related muscle loss)[6].

This is why limiting lean mass loss during treatment is worth taking seriously, and there are well-supported ways to do it.

Two Well-Supported Ways to Limit Lean Mass Loss

Resistance Training

Structured strength (resistance) training, or a mix of resistance and aerobic training, is well established to help preserve lean mass during weight reduction[4].

The mechanism is straightforward: when you stress muscle tissue through resistance exercise, you signal your body to maintain and repair it, even during a caloric deficit.

What the joint advisory recommends:[4]

  • Strength training at least 3 times per week
  • At least 150 minutes of moderate-intensity aerobic activity per week
  • A plan matched to your current fitness level and physical capacity, so you can keep it up

This doesn’t require a gym membership or expensive equipment. Bodyweight exercises (push-ups, squats, lunges), resistance bands, dumbbells, or gym equipment all work. The key is consistency and gradual progression. If you have a health condition or haven’t exercised in a while, check with a licensed provider before starting.

Adequate Protein Intake

Muscle is made of protein. When appetite and food intake drop on a GLP-1 medication, protein intake can drop too, which may contribute to muscle loss[4].

The recommended daily allowance for the general adult population is 0.8 grams per kilogram of body weight per day. The joint advisory notes that higher targets, such as 1.2 to 1.6 grams per kilogram of body weight per day, have been proposed during active weight reduction[4].

For practical reference, using actual body weight, that range works out to:

  • About 80-110 grams of protein per day for a 150-pound person (68 kg)
  • About 110-145 grams of protein per day for a 200-pound person (91 kg)
  • About 135-180 grams of protein per day for a 250-pound person (113 kg)

Two caveats from the advisory: for people with obesity, it is unclear whether targets should be based on actual, adjusted, or lean body weight, and using actual weight can significantly overestimate protein needs; and prolonged intake above 2 g/kg per day should be avoided[4]. Higher targets may not be appropriate for people with chronic kidney disease[7]. A licensed provider or registered dietitian can help you set a target that fits your health.

Good protein sources:

  • Chicken, turkey, lean beef, pork
  • Fish and seafood
  • Eggs
  • Greek yogurt, cottage cheese, milk
  • Beans, lentils, legumes
  • Protein powder (whey, plant-based, etc.)

One practical note: Many people on GLP-1 medications report reduced appetite and difficulty eating larger meals. Protein-first eating, prioritizing protein at each meal before other foods, can help you reach your target without needing to eat huge volumes. The advisory also stresses that more protein alone is likely not enough to preserve muscle without structured strength training[4].

Body Composition in Context: Loose Skin and Lean Mass

One question we hear often: does lean mass loss contribute to loose skin?

Loose skin mainly happens when you lose a large amount of fat. The skin that was stretched by that fat tissue may not retract completely, especially in older adults or after very large weight loss. Whether lean mass loss adds to it has not been well studied. Less muscle underneath can change how the area looks, which is one more reason people focus on resistance training during treatment.

For more detail on this, see our full guide on loose skin and GLP-1 treatment.

Special Considerations: GLP-1 and Older Adults

If you’re 50 or older, lean mass loss deserves extra attention. Here’s why:

Muscle mass declines naturally with age. When severe, this is called sarcopenia, and it is a real clinical concern for older adults. The joint advisory lists older age, menopause or perimenopause, lower testosterone, a sedentary lifestyle, and lack of strength training as factors that raise the risk of muscle loss and sarcopenia with low protein intake[4], and a 2024 review notes that older age may affect who is a good candidate for these medications[6].

In the SURMOUNT-1 body-composition substudy, the share of weight lost as lean mass was fairly consistent across age groups, including people 65 and older[5]. That is one small substudy, and it does not show how strength or function changed.

For older adults, resistance training and adequate protein are especially important, and the joint advisory recommends that a provider assess muscle strength, function, and body composition before starting a GLP-1[4].

For a deeper dive on GLP-1 treatment in older adults, including muscle preservation strategies specific to this population, see our guide on GLP-1 for older adults.

What a proper weight loss program should include

Transformation Health is an independent guide; it does not provide care, coaching, or medication. Programs differ in how much support they give around muscle and nutrition. Based on the joint advisory’s recommendations[4], here is what to ask any program you are considering:

  • Baseline assessment. Does the provider review your usual diet, activity level, and strength training, and consider muscle strength, function, or body composition before starting?
  • Nutrition support. Is counseling with a registered dietitian nutritionist available, and is it included or billed separately?
  • Exercise guidance. Will anyone help you build a strength training plan that fits your fitness level?
  • Side-effect follow-up. How do you reach the provider if nausea or low appetite makes it hard to eat enough protein, and who decides on dose changes?
  • Total cost. Prices vary by program and dose. Compare the total cost: medication, dose increases, visits, labs, shipping, membership fees, and cancellation terms.

At most telehealth programs, a licensed provider decides whether a prescription is appropriate.

Safety Information From the FDA Labels

Any discussion of benefits should include the risks. These points come from the current FDA prescribing information for Wegovy (semaglutide) and Zepbound (tirzepatide)[8][9].

Boxed warning and who should not use them. Both labels carry a boxed warning about thyroid C-cell tumors seen in rodents. It is unknown whether either medication causes these tumors, including medullary thyroid carcinoma, in humans. Neither should be used by people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, or by people with a known serious allergy to the medication or its ingredients.

Other warnings. Both labels warn about acute pancreatitis, gallbladder disease, low blood sugar when used with insulin or sulfonylureas, kidney injury from dehydration, severe stomach and bowel reactions, serious allergic reactions, diabetic retinopathy complications in people with type 2 diabetes, and the risk of inhaling stomach contents during anesthesia or deep sedation. The Wegovy label also lists heart rate increase.

Common side effects. The most common side effects on both labels include nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, fatigue, burping, hair loss, and acid reflux.

For side-effect rates side by side, see semaglutide vs tirzepatide side effects.

The Bottom Line: Muscle Loss Is Real, But Manageable

Yes, lean mass loss happens during GLP-1 treatment. In the trial body-composition analyses, roughly a quarter to two-fifths of the weight lost was lean mass, and not all of that was muscle. That’s real, and it’s worth taking seriously.

But this is not unique to GLP-1 medications. Similar losses are seen with other approaches that produce large weight reductions. Resistance training combined with adequate protein is the approach expert groups recommend to help shift the composition of that weight loss in your favor[4].

Whether you choose semaglutide or tirzepatide, there is no head-to-head evidence that one preserves muscle better than the other. What you can control is what you do during treatment: the resistance training you perform, the protein you eat, and the follow-up you get from the licensed provider you choose. Results vary.

That’s where you have the most say.


About 25%
Lean mass share of weight lost
SURMOUNT-1 DXA substudy, tirzepatide, 72 weeks
About 38%
Lean mass share of weight lost
STEP 1, semaglutide 2.4 mg, per 2025 joint advisory
20.2% vs 13.7%
Weight loss, SURMOUNT-5
Tirzepatide vs semaglutide, 72 weeks; no body composition reported
1.2-1.6g/kg
Daily protein target proposed
During active weight reduction (2025 joint advisory)

The two lean mass figures come from separate trials and cannot be compared directly. Results vary.


What Increases Lean Mass Loss Risk

The joint advisory lists these factors[4]:

  • No strength training during treatment
  • Low protein intake, often from reduced appetite
  • A larger calorie deficit or a faster pace of weight loss
  • Older age, menopause or perimenopause, or lower testosterone
  • A sedentary lifestyle

What Reduces Lean Mass Loss

  • Regular strength training (at least 3 sessions per week in the joint advisory’s recommendation)[4]
  • Adequate protein intake (1.2-1.6 g/kg per day has been proposed during active weight reduction; ask a provider about your target)[4]
  • Aerobic activity (at least 150 minutes per week of moderate intensity)[4]
  • Nutrition support (the joint advisory lists registered dietitian counseling as a supportive strategy)[4]
  • A moderate, steady pace of weight loss[4]

We're relaunching soon

We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.

Get Started

Transformation Health does not accept payment from providers. How we make money.


Learn more about protecting muscle during GLP-1 treatment:


Frequently Asked Questions

Do GLP-1 medications cause muscle loss?

GLP-1 medications are associated with lean mass loss as part of overall weight loss, but this is not unique to these drugs. Both the Wegovy and Zepbound labels state that the medication lowers body weight with greater fat mass loss than lean mass loss. In trial body-composition analyses, about 25% (SURMOUNT-1, tirzepatide) to about 38% (STEP 1, semaglutide) of the weight lost was lean mass, which includes muscle, organs, bone, and water, not only muscle. A 2025 joint advisory from four obesity and nutrition societies notes that similar losses are seen with other approaches that produce large weight reductions, such as bariatric surgery and very low-calorie diets, and recommends resistance training and adequate protein to help preserve muscle. Results vary.

Does tirzepatide cause more muscle loss than semaglutide?

No one can say yet. No head-to-head trial has compared body composition on the two medications, and we did not find one in a PubMed search on October 16, 2026. SURMOUNT-5, the head-to-head trial, reported weight and waist circumference, not lean mass. The separate STEP 1 and SURMOUNT-1 body-composition analyses reported different lean mass shares (about 38% and about 25%), but they studied different people with different methods, so the numbers cannot be compared directly. Because tirzepatide produced more total weight loss in SURMOUNT-5, the absolute amount of lean mass lost could be larger even if the share were similar, but that has not been measured.

How can I minimize muscle loss while on a GLP-1 medication?

Resistance training and adequate protein are the two strategies most often recommended. A 2025 joint advisory recommends strength training at least 3 times a week plus at least 150 minutes of moderate aerobic activity, and notes that protein targets of 1.2 to 1.6 grams per kilogram of body weight per day have been proposed during active weight reduction. It also notes that protein alone is likely not enough without structured strength training. Talk with a licensed provider or a registered dietitian about targets that fit your health, especially if you have kidney disease.

What if I’m new to resistance training? Can I start during GLP-1 treatment?

Yes, many people start during treatment. You don’t need to be experienced or fit. A trainer or physical therapist can help you learn proper form; start with a manageable intensity and progress gradually. If you have a health condition, joint problems, or haven’t exercised in a while, check with a licensed provider first.

How much protein is too much?

The joint advisory notes that 1.2-1.6 g/kg per day has been proposed during active weight reduction, that using actual body weight can overestimate needs in people with obesity, and that prolonged intake above 2 g/kg per day should be avoided. It also notes that excess protein beyond what muscle needs can be converted to fat by the liver. People with kidney disease may need different targets. A licensed provider or registered dietitian can help you set a number that fits your health.

Does muscle loss happen faster at higher GLP-1 doses?

It has not been shown directly. The joint advisory notes that lean mass loss is affected by how large the calorie deficit is, how quickly weight comes off, and whether you do strength training. In the SURMOUNT-1 body-composition substudy, the share of weight lost as lean mass stayed fairly consistent across groups that lost different amounts of weight. Resistance training and nutrition matter at every dose.

Can I preserve muscle on GLP-1 without a gym membership?

Yes. Resistance training can be done with bodyweight (push-ups, squats, lunges), resistance bands, dumbbells, or any combination. You don’t need fancy equipment. The key is consistency, progression (gradually making it harder), and working all major muscle groups; the joint advisory recommends strength training at least 3 times per week.

Is loose skin from muscle loss or fat loss?

Mostly fat loss. Loose skin happens when large amounts of fat are lost, especially in older adults, because stretched skin may not fully retract. Whether lean mass loss adds to it has not been well studied, though less muscle underneath can change how an area looks.


Citations

[1] Wilding JPH, Batterham RL, Calanna S, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/

[2] Jastreboff AM, Aronne LJ, Ahmad NN, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/

[3] Aronne LJ, Horn DB, le Roux CW, et al. “Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.” N Engl J Med. 2025;393(1):26-36. https://pubmed.ncbi.nlm.nih.gov/40353578/

[4] Mozaffarian D, Agarwal M, Aggarwal M, et al. “Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society.” Obes Pillars. 2025;15:100181. https://pubmed.ncbi.nlm.nih.gov/40673264/ (Corrections published 2026.)

[5] Look M, Dunn JP, Kushner RF, et al. “Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.” Diabetes Obes Metab. 2025;27(5):2720-2729. https://pubmed.ncbi.nlm.nih.gov/39996356/ (Correction: Diabetes Obes Metab. 2025;27(11):6823.)

[6] Neeland IJ, Linge J, Birkenfeld AL. “Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies.” Diabetes Obes Metab. 2024;26 Suppl 4:16-27. https://pubmed.ncbi.nlm.nih.gov/38937282/

[7] Arslan S. “Medical nutrition in the glucagon-like peptide-1 (GLP-1) era: Protein strategies, micronutrient monitoring, and lean mass preservation.” Clin Nutr ESPEN. 2026;73:103305. https://pubmed.ncbi.nlm.nih.gov/42036071/

[8] U.S. Food and Drug Administration. WEGOVY (semaglutide) injection and tablets, prescribing information. Revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf

[9] U.S. Food and Drug Administration. ZEPBOUND (tirzepatide) injection, prescribing information. Revised 08/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf

Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Transformation Health is an independent GLP-1 guide. It does not provide medical care, prescribe, compound, or sell medication. A licensed provider decides whether a prescription is appropriate. Clinical trial data on this page (STEP 1, SURMOUNT-1, SURMOUNT-5) applies to the FDA-approved products studied. Results vary. Trial results describe study participants and are not a prediction for any individual. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy or Zepbound and may differ in formulation, purity, and potency. Wegovy is a trademark of Novo Nordisk A/S. Zepbound is a trademark of Eli Lilly and Company. Transformation Health is not affiliated with or endorsed by these companies. Transformation Health does not accept payment from providers. How we make money.

FAQ

Frequently Asked Questions

Everything you need to know about getting started.

Still have questions?

Contact our support team
Do GLP-1 medications cause muscle loss?
GLP-1 medications are associated with lean mass loss as part of overall weight loss, but this is not unique to these drugs. Both the Wegovy and Zepbound labels state that the medication lowers body weight with greater fat mass loss than lean mass loss. In trial body-composition analyses, about 25% (SURMOUNT-1, tirzepatide) to about 38% (STEP 1, semaglutide) of the weight lost was lean mass, which includes muscle, organs, bone, and water, not only muscle. A 2025 joint advisory from four obesity and nutrition societies notes that similar losses are seen with other approaches that produce large weight reductions, such as bariatric surgery and very low-calorie diets, and recommends resistance training and adequate protein to help preserve muscle. Results vary.
Does tirzepatide cause more muscle loss than semaglutide?
No one can say yet. No head-to-head trial has compared body composition on the two medications, and we did not find one in a PubMed search on October 16, 2026. SURMOUNT-5, the head-to-head trial, reported weight and waist circumference, not lean mass. The separate STEP 1 and SURMOUNT-1 body-composition analyses reported different lean mass shares (about 38% and about 25%), but they studied different people with different methods, so the numbers cannot be compared directly. Because tirzepatide produced more total weight loss in SURMOUNT-5, the absolute amount of lean mass lost could be larger even if the share were similar, but that has not been measured.
How can I minimize muscle loss while on a GLP-1 medication?
Resistance training and adequate protein are the two strategies most often recommended. A 2025 joint advisory recommends strength training at least 3 times a week plus at least 150 minutes of moderate aerobic activity, and notes that protein targets of 1.2 to 1.6 grams per kilogram of body weight per day have been proposed during active weight reduction. It also notes that protein alone is likely not enough without structured strength training. Talk with a licensed provider or a registered dietitian about targets that fit your health, especially if you have kidney disease.

We're relaunching soon

We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.

Get Started

About This Site: Disclosures

Who We Are

transformationhealth.com is a website operated by Amerigo Health LLC. Transformation Health is an independent publisher. It does not provide medical care, prescribe, or sell medication, and does not give medical advice. Providers and programs mentioned on this site are independent third parties.

How We Make Money

Transformation Health does not accept payment from providers.

Educational Purpose

This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Results vary. Trial results describe study participants and are not a prediction for any individual.

Compounded Medications

Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy, Ozempic, Zepbound, or Mounjaro. They may differ in formulation, purity, and potency.

Trademarks

Wegovy and Ozempic are trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are trademarks of Eli Lilly and Company. Transformation Health is not affiliated with or endorsed by these companies.